Profile

Cover photo
The Cheap Investor
55 followers|16,970 views
AboutPostsPhotosVideos

Stream

The Cheap Investor

Shared publicly  - 
 
The CHEAP Philosophy to Uncovering Extreme Value - One of the best stocks to own over the last few years wasn’t very exciting… It didn’t have a cure for cancer or anything that was revolutionary.  Nothing head turning…  It’s not as if we uncovered the next Apple or Amazon.  But what I did uncover was extreme value, a stock selling for 77% less than its $10 high, when it was a Wall Street favorite.  . The company – TeleCommunication Systems Inc. (TSYS) – builds communications networks for th...
One of the best stocks to own over the last few years wasn’t very exciting… It didn’t have a cure for cancer or anything that was revolutionary. Nothing h
1
Add a comment...

The Cheap Investor

Shared publicly  - 
 
What Smart Investors Know about Coal Industry Defaults - The Dow Jones (DJIA) closed above 18,000 for the first time since July 2015.  All would seem well for the average investor… or so we think. Unfortunately, the stock market and the economy seem to be moving in opposite directions.  For example, even as stock prices rally near historic highs, corporations are defaulting on debt at levels not seen since the financial crisis of 2008.  In fact, in the first four months of 2016, more than 4...
The Dow Jones (DJIA) closed above 18,000 for the first time since July 2015. All would seem well for the average investor… or so we think. Unfortunately,
1
Add a comment...

The Cheap Investor

Shared publicly  - 
 
Doha 2016 Failure: Why Oil is moving up Anyway… - The Dow Jones Industrial Average (DJIA) topped 18,000 for the first time since July 2015.  It’s now within striking distance of its all-time high of 18,351. That’s a stark change from where 2016 began, thanks in part to the oil rally from a low of $26.05 to more than $42.88 a barrel.  Much of that rally was attributed to bullish speculation that an oil production agreement could be made at the April 17, 2016 Doha meeting with OPEC and non-OP...
The Dow Jones Industrial Average (DJIA) topped 18,000 for the first time since July 2015. It’s now within striking distance of its all-time high of 18,351
1
Add a comment...

The Cheap Investor

Shared publicly  - 
 
Dow Jones Near All-Time Highs, But there are Dangers - In January 2016, the Dow Jones Industrial Average lost up to 2,200 points. Since then, the index has had a tremendous 16% rally from 15,503 to more than 17,926.  Stocks have rebounded well out of bear market territory. Oil has rallied from a low of $26.05 to a high of $42.65 on hopes OPEC and non-OPEC countries can curtail the supply-demand fiasco. Emerging market stocks are also on the cusp of breaking out into bull market territory. A...
In January 2016, the Dow Jones Industrial Average lost up to 2,200 points. Since then, the index has had a tremendous 16% rally from 15,503 to more than 17
1
Add a comment...

The Cheap Investor

Shared publicly  - 
 
Chart of Day: The “Recovery” is just an Illusion… - There’s nothing real about the U.S. recovery. Markets may have rallied well off January 2016 lows, but there’s a great deal of underlying weakness.  “This economy would have to improve dramatically to get to mediocre,” noted Peter Schiff early Monday morning. “The Fed can’t raise rates because they don’t’ want to poke too many holes in this bubble,” he continued.  “This recovery was never real, it’s phony, it’s just another Federal Reserve...
There’s nothing real about the U.S. recovery. Markets may have rallied well off January 2016 lows, but there’s a great deal of underlying weakness. “This
1
Add a comment...

The Cheap Investor

Shared publicly  - 
 
Biotech 2016: M&A Activity Heating Up… Again - After more than $605 billion worth of mergers and acquisitions (M&A), 2015 became the hottest on record for the biotech and pharmaceutical industry. Even though the first quarter of 2016 showed slower M&A activity, I can assure you the trend is far from over. Just last year, AbbVie (ABBV) paid $21 billion for Pharmacyclics, a price that many analysts deemed “astronomical.”  Teva Pharmaceuticals (TEVA) paid $40 billion for Allergan’s (AGN) gener...
After more than $605 billion worth of mergers and acquisitions (M&A), 2015 became the hottest on record for the biotech and pharmaceutical industry. Ev
1
Add a comment...
Have them in circles
55 people
Kedai Komoditi's profile photo
South East Property Depot's profile photo
PrecisionConnections's profile photo
Charles  Francis's profile photo
Perry Immerman's profile photo
Jim Adkison's profile photo
Алевтина Бахчеван's profile photo
husamest's profile photo
JoanAnn Malarkey's profile photo

The Cheap Investor

Shared publicly  - 
 
Chart of Day: How we turned $5,000 into $230,000 - It’s been one of the hottest biotechs we’ve bought over the last five years… Since recommending ACADIA Pharmaceuticals (ACAD) at $1.05 and $1.24 in 2010, we’ve watched the stock soar to $51.99 for gains of 4,851% and 4,093%. Every $1,000 risked is now worth well over $45,000. Every $5,000 risked is now well over $230,000. Those are life-changing returns. We can’t overlook that. What’s interesting is the run, in our opinion, is far from over...
It’s been one of the hottest biotechs we’ve bought over the last five years… Since recommending ACADIA Pharmaceuticals (ACAD) at $1.05 and $1.24 in 2010, w
1
Add a comment...

The Cheap Investor

Shared publicly  - 
 
Chart of Day: NanoViricides Returns 180% - Sometimes the most beautiful returns come from the most ignored stocks on the market. We’ve proven that dozens of times over the last 30+ years, in fact. For example, in the October 2015 edition of The Cheap Investor, we noted NNVC was being ignored 46% off June 2015 highs.  After finding that it had several drug candidates in various stages of FDA approval, a large amount of cash on hand, and recent insider buying by the company’s largest sharehol...
Sometimes the most beautiful returns come from the most ignored stocks on the market. We’ve proven that dozens of times over the last 30+ years, in fact. F
1
Add a comment...

The Cheap Investor

Shared publicly  - 
 
Chart of Day: Pain Therapeutics (PTIE) Recovering - In late 2014, shares of Pain Therapeutics plunged from a high of $4.25 to less than $1.75 after Pfizer ended an agreement to help it develop and market the Remoxy pain drug along with Durect Corporation.  Since then, PTIE has been greatly ignored.  However, in July 2015, we found value, recommending the stock at just $1.83.  Last checked, it traded at a $2.39 high for potential gains of 31%.  At the moment, we’re anticipating higher highs,...
In late 2014, shares of Pain Therapeutics plunged from a high of $4.25 to less than $1.75 after Pfizer ended an agreement to help it develop and market the
1
Add a comment...

The Cheap Investor

Shared publicly  - 
 
Oil Reaches 2016 Highs… But will the Rally Last? - Hitting a high of $144.32 in 2008, oil slipped 82% to $26.05 just eight years later. Why?  Supply outweighed demand.  Storage levels at Cushing (the world’s largest crude oil storage facility) neared full capacity, renewing concerns the price of oil could come under intense pressure.  The U.S. oil patch suffered, and tens of thousands of jobs were lost.  Investors, insiders, and billionaires bet on the upside – calling for higher oil prices...
Hitting a high of $144.32 in 2008, oil slipped 82% to $26.05 just eight years later. Why? Supply outweighed demand. Storage levels at Cushing (the world’
1
Add a comment...

The Cheap Investor

Shared publicly  - 
 
Q1 2016 in Review: What Investors Must Understand - The first quarter of 2016 came in a whimper and ended with a bang… In the first week of the year, the Dow Jones fell 2,200 points, wiping out trillions of shareholder value.  Investors had many concerns — the China slowdown, falling oil and commodity prices, and the Federal Reserve’s actions.  Fears of a global recession raged in the headlines, as markets plummeted well into bear market territory. Consumer spending was weak.  Manufacturing...
The first quarter of 2016 came in a whimper and ended with a bang… In the first week of the year, the Dow Jones fell 2,200 points, wiping out trillions of
1
Add a comment...

The Cheap Investor

Shared publicly  - 
 
Chart of Day: A Biotech M&A Boom in the Making - Biotech may have had a rough start to the year, lagging many other sectors. But don’t count it out just yet.  In fact, buy all you can.  The same strong catalysts and fundamentals are still firmly in place. There are 80 million baby boomers that just started retiring.  We have millions of newly insured American, new innovation, new drug demand, an older generation needing new treatment to help with costly ailments, and an M&A boom that produc...
Biotech may have had a rough start to the year, lagging many other sectors. But don’t count it out just yet. In fact, buy all you can. The same strong ca
1
Add a comment...
People
Have them in circles
55 people
Kedai Komoditi's profile photo
South East Property Depot's profile photo
PrecisionConnections's profile photo
Charles  Francis's profile photo
Perry Immerman's profile photo
Jim Adkison's profile photo
Алевтина Бахчеван's profile photo
husamest's profile photo
JoanAnn Malarkey's profile photo
Contact Information
Contact info
Phone
(877) 306-4256
Email
Story
Tagline
Founded in 1981 by Bill Mathews, The Cheap Investor newsletter is all about discovering quality stocks trading for less than $5 per share.
Introduction
Since 1981, The CHEAP Investor newsletter has been an intelligent and straightforward guide to choosing low-price quality stocks and has helped thousands of investors make profitable investment decisions. Subscribers get the information that they need to purchase stocks with great profit potential at the lowest price. The CHEAP Investor was rated the #1 Best Performing Market Letter for the five-year period ending November 2006, by Select Information Exchange and one of the four best small stock advisories in America by the League of American Investors.


Bill Mathews
Recognized as one of the foremost authorities on investing in small-cap stocks, Bill Mathews has been a frequent guest on radio and television shows nationwide such as CNBC. He has been interviewed by major newspapers and magazines including the Wall Street Journal, Business Week, Barrons and the Chicago Tribune. Bill Mathews is the author of the book "Making Big Money in Small Stocks" which describes specific techniques for analyzing stocks easily and profitably as well as determining what might affect a stock's profit potential. Mr. Mathews also taught securities analysis for the MBA program at the Keller Graduate School of Management, and spent 15 years teaching business and investment courses at Triton College.